BAX 326 (Recombinant Factor IX): A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B Undergoing Surgical or Other Invasive Procedures
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006638/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to assess the hemostatic efficacy and safety of BAX 326 in
subjects with severe (FIX level < 1%) or moderately severe (FIX level 1-2%) hemophilia B
undergoing major or minor elective or emergency surgical, dental or other invasive
procedures.
提供机构：
Vivli
创建时间：
2021-02-02
